Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Latest Senate FDA Reform Bill Would Delay Guidance On Mobile Health Apps

This article was originally published in The Gray Sheet

Executive Summary

The Senate user fee reauthorization and FDA reform bill, formally introduced May 15, includes several new provisions, including a moratorium on FDA issuing final guidance on mobile medical apps. The bill should see action on the Senate floor this week.


Related Content

Challenges Abound In Creating Regulatory Framework For Mobile Medical Apps, Health IT
FDA Subject To More Oversight Following User Fee Bill Passage
A Successful Pharma Mobile Strategy Means Matching The Right Info To The Right Device
U.S. mHealth Stakeholders Seek To Eliminate Barriers To Growth
IBM Watson Exec Eyes Oncology Advisors Pilot
FDA User Fee Reauthorization Charges Along With Senate Passage
Brookings Workshop Explores Cultural Changes Needed To Drive mHealth
Fireworks Kept At Bay As Congress Pushes To Enact FDA Reforms By July 4
Senate Committee Moves Bipartisan FDA Reform Bill Toward Floor
Industry Applauds FDA Draft Guidance On Mobile Medical Apps





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts